Dx’d August 2021. Radical prostatectomy with extended LN dissection 09/2021, = pT3bN1; 8/27 metastatic nodes,...

TL;DR: Your prostate cancer has responded very well to treatment twice now, with your PSA dropping to undetectable levels both times—this is an excellent sign, but you'll need ongoing monitoring since PSA can rise again.

KEY POINTS:

• Your initial surgery removed the primary tumor and many affected lymph nodes, and you've now had two successful rounds of systemic therapy (hormone therapy + chemotherapy) that brought your PSA to undetectable levels
• The fact that your cancer responded well the second time after PSA rose again suggests your cancer remains treatable, which is an encouraging prognostic indicator
• You're currently in a "remission" state with PSA <0.01, but prostate cancer can recur, so regular PSA monitoring and imaging will be essential going forward
• Your treatment team used advanced imaging (PSMA-PET CT) to find small metastatic lymph nodes and targeted them with SBRT (stereotactic radiation), showing a precision approach to managing recurrence
• The pattern of your response suggests discussing with your oncologist what the surveillance plan looks like now and what PSA level would trigger next intervention

NEXT STEP: Schedule a follow-up appointment with your medical oncologist to discuss your surveillance schedule (PSA monitoring frequency, imaging intervals) and establish clear PSA thresholds that would prompt discussion of next treatment steps.

[[FULL_ANSWER]]

Understanding Your Prostate Cancer Journey

Your medical history shows a complex but very treatable prostate cancer that has demonstrated excellent response to multimodal therapy—twice. Let me walk through what this means educationally.

Your Initial Diagnosis & Surgery (August-September 2021)

You were diagnosed with locally advanced, node-positive prostate cancer (stage pT3bN1). The pathology findings were significant:

• pT3b: Cancer extended beyond the prostate capsule into the seminal vesicles (SVI = seminal vesicle invasion)
• N1: Cancer had spread to regional lymph nodes (you had 8 out of 27 nodes involved)
• Additional aggressive features: Intraductal carcinoma, lymphovascular invasion (LVI), extraprostatic extension (EPE), perineural invasion (PNI)—these are markers of more aggressive biology

Your pre-surgery PSA of 42 ng/mL was elevated (normal is <4), reflecting the tumor burden. The radical prostatectomy with extended lymph node dissection removed the primary tumor and regional nodes. Your post-surgery PSA of 4.0 ng/mL indicated some residual disease remained (likely micrometastatic disease not visible on imaging).

First Treatment Course (November 2021 - November 2023)

You received a multimodal approach:

• ADT (androgen deprivation therapy) + abiraterone: Hormone therapy blocking testosterone production and signaling, plus abiraterone (which blocks additional androgen synthesis). This is standard for node-positive disease.
• WPRT (whole pelvis radiation therapy): 40 sessions of intensity-modulated radiation therapy (IMRT) targeting the pelvis where lymph nodes were involved
• Duration: 2-year course of systemic therapy

Result: You achieved a PSA nadir <0.01 ng/mL—essentially undetectable. This is an excellent response and indicates the cancer was very sensitive to this combination approach.

According to NCCN Guidelines for Prostate Cancer, patients with node-positive disease who achieve undetectable PSA after multimodal therapy have significantly improved outcomes compared to those with persistent PSA elevation.

Recurrence & Second Treatment (Mid-2024 - October 2026)

In mid-2024, your PSA began rising slowly, reaching 0.65 ng/mL by April 2026. This represents biochemical recurrence—the cancer was growing again, though at a relatively slow pace (the gradual rise over ~18 months is actually a favorable kinetic pattern).

Imaging findings: PSMA-PET CT detected two metastatic lymph nodes at the L4-5 region (lower lumbar spine area). PSMA-PET is a highly sensitive imaging modality that can detect very small disease burden.

Second treatment approach:

• Re-initiated systemic therapy: Same hormone therapy + abiraterone regimen
• SBRT (stereotactic body radiation therapy): Targeted high-dose radiation to the two identified lymph nodes

Current status: You've again achieved PSA nadir <0.01 as of October 2026.

What This Pattern Means Educationally

1. Excellent Treatment Sensitivity Your cancer responded dramatically to systemic therapy twice. The fact that it responded the second time after recurrence is a very positive prognostic indicator. According to ASCO Guidelines on Castration-Resistant Prostate Cancer, patients who maintain sensitivity to hormone therapy and achieve undetectable PSA have substantially better outcomes than those with primary hormone resistance.

2. Oligometastatic Disease Pattern Your recurrence involved only 2 lymph nodes detected on advanced imaging. This "oligometastatic" pattern (limited number of metastases) is increasingly recognized as potentially curable with aggressive local therapy (SBRT). The combination of systemic therapy + targeted radiation represents a modern precision approach.

3. Slow PSA Kinetics The gradual rise from <0.01 to 0.65 over 18 months is relatively slow. PSA doubling time and velocity are prognostic factors—faster rises suggest more aggressive biology. Your slower trajectory is favorable.

4. Importance of Advanced Imaging The PSMA-PET CT identified disease that might not have been visible on conventional imaging. This allowed targeted treatment of specific sites rather than empiric whole-pelvis radiation.

What Happens Now: The Surveillance Question

You're currently in a remission state with undetectable PSA. However, prostate cancer can recur again, and your history shows this pattern. The critical questions for your oncology team are:

1. What is the surveillance plan? How frequently should PSA be checked (typically every 3-6 months initially)?
2. What imaging intervals are planned? Will you have repeat PSMA-PET CT, conventional imaging, or both?
3. What PSA threshold triggers next intervention? (e.g., "If PSA reaches 0.5 ng/mL, we'll discuss next steps")
4. How long will you continue current systemic therapy? Some patients continue indefinitely; others have planned stops.
5. If PSA rises again, what's the next treatment strategy? Are there other systemic options, additional radiation sites, or clinical trials to consider?

Educational Context: Your Prognosis

According to the American Cancer Society and NCCN Guidelines, patients with node-positive prostate cancer who:

• Achieve undetectable PSA after multimodal therapy
• Maintain sensitivity to hormone therapy
• Have oligometastatic recurrence

...have substantially improved survival compared to historical controls. However, prostate cancer is often a chronic disease requiring long-term management, and your case demonstrates this—you've had excellent responses but require ongoing surveillance.

Questions to Ask Your Oncology Team

1. "Based on my response pattern, what does my long-term prognosis look like, and what factors would change that?"
2. "What is my specific surveillance schedule for PSA and imaging over the next 12-24 months?"
3. "At what PSA level should we discuss next treatment options?"
4. "Are there any clinical trials I should consider given my history of good response to systemic therapy?"
5. "How long should I continue my current systemic therapy, and what are the pros/cons of stopping versus continuing?"
6. "If PSA rises again, what treatment options would be available, and in what order would you consider them?"

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.